Description:
Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively. It is used in the treatment of certain types of cancer, mostly metastatic breast cancer, acute myeloid leukemia, and non-Hodgkin's lymphoma.
- Molecular Weight: 444.48
- Molecular Formula: C22H28N4O6
Purity: >98%
Canonical SMILES:
C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
InChI:
InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
InChIKey: KKZJGLLVHKMTCM-UHFFFAOYSA-N
- Boiling Point: 805.7±65.0 °C at 760 mmHg
- Melting Point: 170-174°C
- Solubility: In vitro: 10 mM in DMSO
- Appearance: Brown to black (Solid)
- Application: Analgesics
- Storage: 4°C, protect from light* In solvent : -80°C, 6 months-20°C, 1 month (protect from light)
Synonyms:
mitoxantrone; 65271-80-9; Mitoxanthrone; Mitozantrone; DHAQ
More details are to be found on supplier website
